This biomarker is also known as:
- Histone H2B.g,
- Histone H2B.h,
- histone 1, H2bf,
- histone cluster 1, H2bf,
- Histone H2B.a,
- histone H2B type 1-C/E/F/G/I,
- H2B histone family, member G,
- Histone H2B.k,
- Histone H2B.l,
- histone H2B.1 A,
- histone H2B.g,
- Histone H2B.1 A,
View in BioMuta
histone cluster 1, H2bf
There are no datasets associated with this biomarker.
The following organs have data associated with this biomarker…
Significance Analysis of Microarray (SAM) was used to develop a 7-gene classifier. The overall prediction accuracy and sensitivity is 71% and 76%, respectively. The inclusion of the Gleason sum to the seven-gene classifier raised the prediction accuracy and sensitivity to 83% and 76% respectively This prognostic signature is closely associated with biochemical recurrence in patients after radical prostatectomy. The seven genes are: RRAGD, PQBP1, HIST1H2BC (HIST1H2BE, HIST1H2BF, HIST1H2BI), ALDH1A2, TRIM22, RBPMS, HSPB8.
This biomarker is currently being annotated or is under review.
You must be logged in
or do not have permission to view any additional information. Contact Heather Kincaid at
if you should have access to this biomarker.
Update: Pre-application webinar information now available.
The National Cancer Institute's Division of Cancer Prevention has released a new funding opportunity to solicit organ-specific applications for Biomarker Developmental Laboratories (BDLs), one of the four scientific units of the recently funded Early Detection Research Network (EDRN). The EDRN is a national infrastructure funded to discover, develop, and validate biomarkers for risk assessment, detection, and molecular diagnosis and prognosis of early cancer. BDLs are responsible for the discovery, development, characterization, and testing of new, or the refinement of existing, biomarkers and biomarker assays for risk assessment, detection, and molecular diagnosis and prognosis of cancers.
The existing BDLs are primarily focused on ovary and gastrointestinal cancers. The proposed BDLs (to be supported under this funding opportunity) should be focused on one or more of the following cancers: breast, prostate and other genitourinary organs, or lung. In addition, cancers with rapidly rising incidence rates, e.g., endometrial, hepatocellular, kidney, thyroid, oropharyngeal cancers, and/or cancers with unique etiology, e.g., mesothelioma, will be considered.
The newly funded units of the Early Detection Research Network will be announced later in April. Successful applicants have already been notified. Those researchers who were not successful during the last round of applications are encouraged to apply to this opportunity.